KRAS and non-small cell lung carcinoma: Furthermore, following the accelerated approval, the results of the confirmatory phase 3 trial (CodeBreak 200) comparing sotorasib (960 mg) to docetaxel in advanced pretreated KRAS G12C mutated NSCLC did not show an improvement of the overall survival, leading to another requirement by the FDA to conduct an additional trial [75].